Stryker’s proposed acquisition of Inari kicks off medtech M&A in 2025 after a flurry of deals last year. Inari, based in Irvine, California, makes a variety of devices including catheter-based ...

In the first weeks of 2022, Stryker Corporation (NYSE:SYK) announced a $3.1 billion deal to acquire Vocera, in an effort to add digital coordination and communication to its line-up of medical ...

Portage, Michigan, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its fourth quarter and full year 2024 on Tuesday, January 28 ...

To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Stryker has agreed to acquire Inari Medical for approximately $4.9 billion, the company announced late Monday.

NEW YORK, Jan 6 (Reuters) - Medical-device maker Stryker (SYK.N), opens new tab on Monday agreed to acquire Inari Medical (NARI.O), opens new tab, which makes devices that treat patients with ...

After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening its pocketbook a bit wider to acquire Inari Medical with its portfolio of ...

Inari Medical Inc., one of Orange County’s fastest-growing medical device makers, is being acquired for $4.9 billion by global medical technology company Stryker Corp. Stryker on Jan. 6 announced an ...

Smith Collection / Gado / Getty Images Shares of Inari Medical surged Monday afternoon and again Tuesday morning as reports of an imminent acquisition by Stryker turned into reality. Stryker will ...

(RTTNews) - Stryker (SYK), Monday said it reached a deal to buy Inari Medical, Inc. (NARI) for $80 per share in cash, representing an equity value of about $4.9 billion. According to Stryker ...

Stryker (SYK) confirmed an agreement to purchase Inari Medical (NASDAQ:NARI) for about $4.9 billion. Inari jumped 21% in after hours trading. The medical devices firm will pay $80 a share in cash ...

Stryker (SYK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Caitlin Cronin from Canaccord Genuity maintained a Buy rating on the ...